The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs.

@article{Roos2009TheTP,
  title={The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs.},
  author={Wynand Paul Roos and Anastasia Tsaalbi-Shtylik and Roman Tsaryk and Fatma G{\"u}vercin and Niels de Wind and Bernd Kaina},
  journal={Molecular pharmacology},
  year={2009},
  volume={76 4},
  pages={927-34}
}
Temozolomide and fotemustine, representing methylating and chloroethylating agents, respectively, are used in the treatment of glioma and malignant melanoma. Because chemoresistance of these tumors is a common phenomenon, identification of the underlying mechanisms is needed. Here we show that Rev3L, the catalytic subunit of the translesion DNA polymerase zeta, mediates resistance to both temozolomide and fotemustine. Rev3L knockout cells are hypersensitive to both agents. It is remarkable that… CONTINUE READING
20 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…